-
Deutsche Bank To Hold 36th Annual Healthcare Conference Next Week
Wednesday, April 27, 2011 - 8:00am | 135According to Deutsche Bank, it will be holding its 36th Annual Healthcare Conference in Boston on May 2nd-4th. Top companies in the healthcare industry will be in attendance, Deutsche Bank explains, “The conference will feature senior managements from many of the leading healthcare companies as...
-
Merck Announces New $5 Billion Share Repurchase Program (MRK)
Wednesday, April 27, 2011 - 7:45am | 68Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that its Board of Directors has approved additional purchases of up to $5 billion of Merck's common stock for its treasury. The treasury stock purchase has no time limit and will be made over time on the open...
-
Watson First Quarter 2011 Net Revenue Increases to $877 Million
Wednesday, April 27, 2011 - 7:07am | 88Watson Pharmaceuticals (NYSE: WPI) today reported net revenue of $876.5 million for the first quarter ended March 31, 2011, compared to $856.5 million in the first quarter 2010. On a non-GAAP basis, net income for the first quarter 2011 was $111.9 million or $0.89 per share, an increase of 12...
-
Watson Pharma Reports EPS of $0.89 vs. $0.86 Estimate; Revenues $876.5M vs. $912.33M Estimate (WPI)
Wednesday, April 27, 2011 - 7:07am | 22Watson Pharma (NYSE: WPI) Reports EPS of $0.89 vs. $0.86 Estimate; Revenues $876.5M vs. $912.33M Estimate
-
Most Active U.S. Stocks right now on April 27 – C, F, BAC, INTC, CSCO, MSFT, GE, PFE, DELL, WFC
Wednesday, April 27, 2011 - 6:37am | 1441Citigroup Inc (C)- 4.51 (Price), -0.01 (Change), -0.22% (% Change)- Citigroup Inc. (Citigroup) is a global diversified financial services holding company. The Company provides consumers, corporations, governments and institutions with a range of financial products and services. As of December...
-
US Stock Futures Up As Investors Await Federal Reserve Chairman's News Conference
Wednesday, April 27, 2011 - 6:32am | 551US stock futures are higher this morning, as investors are awaiting Federal Reserve Chairman's news conference. Futures on the Dow Jones Industrial Average gained 41 points to 12,559.00 and S&P 500 index futures rose 5 points to 1,345.90. Futures on the Nasdaq 100 surged 14.25 points to 2,399....
-
Trading on Johnson & Johnson's $21.3 Billion Purchase of Synthes (JNJ, MDT, BSX, TMO, IHI)
Wednesday, April 27, 2011 - 6:14am | 411New Brunswick, New Jersey-based Johnson & Johnson (NYSE: JNJ) and Synthes, Inc. announced early on Wednesday morning that the two companies had reached an agreement for Johnson & Johnson to buy the Swiss company for 159 Swiss francs per share, or a total of US$21.3 billion at current...
-
CEOWORLD Magazine DAILY BUSINESS AND TECH ROUNDUP- JNJ, SNE, AMAT, AMZN, STX, NWS, MSFT, NDAQ, NYX, NVDA, BP, YHOO
Wednesday, April 27, 2011 - 5:19am | 1076Johnson & Johnson (NYSE: JNJ)- Johnson & Johnson and Synthes, Inc., a manufacturer of orthopaedic devices, announced that they have entered into a definitive agreement whereby Johnson & Johnson will acquire Synthes for CHF159 per share, or $21.3 billion. French nuclear reactor maker...
-
Johnson & Johnson to Acquire Orthopaedic Device Maker Synthes for $21 Billion (JNJ)
Wednesday, April 27, 2011 - 5:13am | 288Johnson & Johnson (NYSE: JNJ) announced Wednesday that it would acquire Synthes, a global manufacturer of orthopaedic devices, for more than $21 billion. Under the terms of the agreement, each share of Swiss-based Synthes common stock will be exchanged for CHF55.65 in cash and CHF103.35 in...
-
Johnson and Johnson Agrees to Buy Swiss Synthes Inc. (SYST) for $21,5 billion
Wednesday, April 27, 2011 - 4:33am | 701Johnson and Johnson (NYSE:JNJ), the world's second-biggest seller of health-care products, has agreed to buy Swiss medical device manufacturer Synthes Inc. (SYST) for $21,5 billion. Johnson and Johnson will acquire Synthes for 19 billion Swiss Francs, or $21.59 billion. Johnson & Johnson is...
-
J&J May Offer $21.3 Billion For Synthes
Wednesday, April 27, 2011 - 2:50am | 288Dow component Johnson & Johnson (NYSE: JNJ) will reportedly offer $21.3 billion for Synthes, the Swiss medical device maker. J&J could unveil the offer as early as Wednesday, the Wall Street Journal reported, citing sources familiar with the matter. New Jersey-based J&J has been...
-
Sanofi-aventis and Regeneron Report Positive Phase III Results With ZALTRAP in Second-line Metastatic Colorectal Cancer
Tuesday, April 26, 2011 - 4:14pm | 112Sanofi-aventis (NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that the Phase III VELOUR trial evaluating the investigational agent ZALTRAP™ , also known as VEGF Trap, in combination with the FOLFIRI chemotherapy regimen, 5-fluorouracil, and irinotecan] versus a...
-
Sanofi-aventis and Regeneron Report Positive Phase III Results With ZALTRAP™ (SNY, REGN)
Tuesday, April 26, 2011 - 4:09pm | 78Sanofi-aventis (NYSE: SNY) and Regeneron Pharmaceuticals (Nasdaq: REGN) today announced that the Phase III VELOUR trial evaluating the investigational agent ZALTRAP™ , also known as VEGF Trap, in combination with the FOLFIRI chemotherapy regimen [folinic acid, 5-fluorouracil, and irinotecan] versus...
-
What's Hot On TheStreet
Tuesday, April 26, 2011 - 2:13pm | 247Here's what Benzinga's reading on our friend, TheStreet.com. What's Hot On TheStreet 10 Bad Investment Ideas You Need to Rethink The public is hungry for guidance when it comes to their retirement strategy. The challenge is avoiding bad advice. Fund Managers Spy Opportunities in Japan Even...
-
Vertex Stock Booms After FDA Reports New Drug is Effective (VRTX)
Tuesday, April 26, 2011 - 2:00pm | 221Vertex (NASDAQ: VRTX) is up more than 10% today on news that the FDA found the pharmaceutical company's Hepatitis C drug was more effective than current drugs on the market. The announcement on the efficacy of telaprevir comes ahead of Thursday's meeting, where the FDA is expected to vote on...